Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy

A multidisciplinary study of peritoneal carcinomatosis

Maciej Nowacki, Marek Wisniewski, Karolina Werengowska-Ciecwierz, Katarzyna Roszek, Joanna Czarnecka, I. Lakomska, Tomasz Kloskowski, Dominik Tyloch, Robert Debski, Katarzyna Pietkun, Marta Pokrywczynska, Dariusz Grzanka, Rafal Czajkowski, Gerard Drewa, A. Jundzill, Joseph K. Agyin, Samy L Habib, Artur P. Terzyk, Tomasz Drewa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In general, detection of peritoneal carcinomatosis (PC) occurs at the late stage when there is no treatment option. In the present study, we designed novel drug delivery systems that are functionalized with anti-CD133 antibodies. The C1, C2 and C3 complexes with cisplatin were introduced into nanotubes, either physically or chemically. The complexes were reacted with anti-CD133 antibody to form the labeled product of A0-o-CX-chem-CD133. Cytotoxicity screening of all the complexes was performed on CHO cells. Data showed that both C2 and C3 Pt-complexes are more cytotoxic than C1. Flow-cytometry analysis showed that nanotubes conjugated to CD133 antibody have the ability to target cells expressing the CD133 antigen which is responsible for the emergence of resistance to chemotherapy and disease recurrence. The shortest survival rate was observed in the control mice group (K3) where no hyperthermic intraperitoneal chemotherapy procedures were used. On the other hand, the longest median survival rate was observed in the group treated with A0-o-C1-chem-CD133. In summary, we designed a novel drug delivery system based on carbon nanotubes loaded with Pt-prodrugs and functionalized with anti-CD133 antibodies. Our data demonstrates the effectiveness of the new drug delivery system and provides a novel therapeutic modality in the treatment of melanoma.

Original languageEnglish (US)
Pages (from-to)22776-22798
Number of pages23
JournalOncotarget
Volume6
Issue number26
StatePublished - 2015

Fingerprint

Drug Delivery Systems
Nanotubes
Anti-Idiotypic Antibodies
Carcinoma
Drug Therapy
Carbon Nanotubes
CHO Cells
Prodrugs
Cisplatin
Melanoma
Flow Cytometry
Therapeutics
Recurrence
Control Groups
Antibodies

Keywords

  • Carcinomatosis
  • Hyperthermic intraperitoneal chemotherapy
  • Intraperitoneal perfusion and nanovehicles
  • Palliative

ASJC Scopus subject areas

  • Oncology

Cite this

Nowacki, M., Wisniewski, M., Werengowska-Ciecwierz, K., Roszek, K., Czarnecka, J., Lakomska, I., ... Drewa, T. (2015). Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: A multidisciplinary study of peritoneal carcinomatosis. Oncotarget, 6(26), 22776-22798.

Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy : A multidisciplinary study of peritoneal carcinomatosis. / Nowacki, Maciej; Wisniewski, Marek; Werengowska-Ciecwierz, Karolina; Roszek, Katarzyna; Czarnecka, Joanna; Lakomska, I.; Kloskowski, Tomasz; Tyloch, Dominik; Debski, Robert; Pietkun, Katarzyna; Pokrywczynska, Marta; Grzanka, Dariusz; Czajkowski, Rafal; Drewa, Gerard; Jundzill, A.; Agyin, Joseph K.; Habib, Samy L; Terzyk, Artur P.; Drewa, Tomasz.

In: Oncotarget, Vol. 6, No. 26, 2015, p. 22776-22798.

Research output: Contribution to journalArticle

Nowacki, M, Wisniewski, M, Werengowska-Ciecwierz, K, Roszek, K, Czarnecka, J, Lakomska, I, Kloskowski, T, Tyloch, D, Debski, R, Pietkun, K, Pokrywczynska, M, Grzanka, D, Czajkowski, R, Drewa, G, Jundzill, A, Agyin, JK, Habib, SL, Terzyk, AP & Drewa, T 2015, 'Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: A multidisciplinary study of peritoneal carcinomatosis', Oncotarget, vol. 6, no. 26, pp. 22776-22798.
Nowacki M, Wisniewski M, Werengowska-Ciecwierz K, Roszek K, Czarnecka J, Lakomska I et al. Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: A multidisciplinary study of peritoneal carcinomatosis. Oncotarget. 2015;6(26):22776-22798.
Nowacki, Maciej ; Wisniewski, Marek ; Werengowska-Ciecwierz, Karolina ; Roszek, Katarzyna ; Czarnecka, Joanna ; Lakomska, I. ; Kloskowski, Tomasz ; Tyloch, Dominik ; Debski, Robert ; Pietkun, Katarzyna ; Pokrywczynska, Marta ; Grzanka, Dariusz ; Czajkowski, Rafal ; Drewa, Gerard ; Jundzill, A. ; Agyin, Joseph K. ; Habib, Samy L ; Terzyk, Artur P. ; Drewa, Tomasz. / Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy : A multidisciplinary study of peritoneal carcinomatosis. In: Oncotarget. 2015 ; Vol. 6, No. 26. pp. 22776-22798.
@article{1c965373f3b14622b58caa45fe3316e0,
title = "Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: A multidisciplinary study of peritoneal carcinomatosis",
abstract = "In general, detection of peritoneal carcinomatosis (PC) occurs at the late stage when there is no treatment option. In the present study, we designed novel drug delivery systems that are functionalized with anti-CD133 antibodies. The C1, C2 and C3 complexes with cisplatin were introduced into nanotubes, either physically or chemically. The complexes were reacted with anti-CD133 antibody to form the labeled product of A0-o-CX-chem-CD133. Cytotoxicity screening of all the complexes was performed on CHO cells. Data showed that both C2 and C3 Pt-complexes are more cytotoxic than C1. Flow-cytometry analysis showed that nanotubes conjugated to CD133 antibody have the ability to target cells expressing the CD133 antigen which is responsible for the emergence of resistance to chemotherapy and disease recurrence. The shortest survival rate was observed in the control mice group (K3) where no hyperthermic intraperitoneal chemotherapy procedures were used. On the other hand, the longest median survival rate was observed in the group treated with A0-o-C1-chem-CD133. In summary, we designed a novel drug delivery system based on carbon nanotubes loaded with Pt-prodrugs and functionalized with anti-CD133 antibodies. Our data demonstrates the effectiveness of the new drug delivery system and provides a novel therapeutic modality in the treatment of melanoma.",
keywords = "Carcinomatosis, Hyperthermic intraperitoneal chemotherapy, Intraperitoneal perfusion and nanovehicles, Palliative",
author = "Maciej Nowacki and Marek Wisniewski and Karolina Werengowska-Ciecwierz and Katarzyna Roszek and Joanna Czarnecka and I. Lakomska and Tomasz Kloskowski and Dominik Tyloch and Robert Debski and Katarzyna Pietkun and Marta Pokrywczynska and Dariusz Grzanka and Rafal Czajkowski and Gerard Drewa and A. Jundzill and Agyin, {Joseph K.} and Habib, {Samy L} and Terzyk, {Artur P.} and Tomasz Drewa",
year = "2015",
language = "English (US)",
volume = "6",
pages = "22776--22798",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy

T2 - A multidisciplinary study of peritoneal carcinomatosis

AU - Nowacki, Maciej

AU - Wisniewski, Marek

AU - Werengowska-Ciecwierz, Karolina

AU - Roszek, Katarzyna

AU - Czarnecka, Joanna

AU - Lakomska, I.

AU - Kloskowski, Tomasz

AU - Tyloch, Dominik

AU - Debski, Robert

AU - Pietkun, Katarzyna

AU - Pokrywczynska, Marta

AU - Grzanka, Dariusz

AU - Czajkowski, Rafal

AU - Drewa, Gerard

AU - Jundzill, A.

AU - Agyin, Joseph K.

AU - Habib, Samy L

AU - Terzyk, Artur P.

AU - Drewa, Tomasz

PY - 2015

Y1 - 2015

N2 - In general, detection of peritoneal carcinomatosis (PC) occurs at the late stage when there is no treatment option. In the present study, we designed novel drug delivery systems that are functionalized with anti-CD133 antibodies. The C1, C2 and C3 complexes with cisplatin were introduced into nanotubes, either physically or chemically. The complexes were reacted with anti-CD133 antibody to form the labeled product of A0-o-CX-chem-CD133. Cytotoxicity screening of all the complexes was performed on CHO cells. Data showed that both C2 and C3 Pt-complexes are more cytotoxic than C1. Flow-cytometry analysis showed that nanotubes conjugated to CD133 antibody have the ability to target cells expressing the CD133 antigen which is responsible for the emergence of resistance to chemotherapy and disease recurrence. The shortest survival rate was observed in the control mice group (K3) where no hyperthermic intraperitoneal chemotherapy procedures were used. On the other hand, the longest median survival rate was observed in the group treated with A0-o-C1-chem-CD133. In summary, we designed a novel drug delivery system based on carbon nanotubes loaded with Pt-prodrugs and functionalized with anti-CD133 antibodies. Our data demonstrates the effectiveness of the new drug delivery system and provides a novel therapeutic modality in the treatment of melanoma.

AB - In general, detection of peritoneal carcinomatosis (PC) occurs at the late stage when there is no treatment option. In the present study, we designed novel drug delivery systems that are functionalized with anti-CD133 antibodies. The C1, C2 and C3 complexes with cisplatin were introduced into nanotubes, either physically or chemically. The complexes were reacted with anti-CD133 antibody to form the labeled product of A0-o-CX-chem-CD133. Cytotoxicity screening of all the complexes was performed on CHO cells. Data showed that both C2 and C3 Pt-complexes are more cytotoxic than C1. Flow-cytometry analysis showed that nanotubes conjugated to CD133 antibody have the ability to target cells expressing the CD133 antigen which is responsible for the emergence of resistance to chemotherapy and disease recurrence. The shortest survival rate was observed in the control mice group (K3) where no hyperthermic intraperitoneal chemotherapy procedures were used. On the other hand, the longest median survival rate was observed in the group treated with A0-o-C1-chem-CD133. In summary, we designed a novel drug delivery system based on carbon nanotubes loaded with Pt-prodrugs and functionalized with anti-CD133 antibodies. Our data demonstrates the effectiveness of the new drug delivery system and provides a novel therapeutic modality in the treatment of melanoma.

KW - Carcinomatosis

KW - Hyperthermic intraperitoneal chemotherapy

KW - Intraperitoneal perfusion and nanovehicles

KW - Palliative

UR - http://www.scopus.com/inward/record.url?scp=84941241927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941241927&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 22776

EP - 22798

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -